Concord Biotech, 543960, CONCORDBIO Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

15,505.17
56.31
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

15,491.59
0.51%
7.48

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

12.61
8.15
1.23

EBITDA CAGR (%)

10 Years
5 Years
3 Years

8.58
6.08
-3.17

PAT CAGR (%)

10 Years
5 Years
3 Years

9.24
8.32
-5.39

P:E (Median)

8 Years
5 Years
3 Years

-
-
52.89

P:BV (Average)

8 Years
5 Years
3 Years

-
-
9.53

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
34.67

Earnings Forecasts:

(Updated: 22-08-2026)

Description 2026 2027 2028 2029
Adj EPS 31 -2 18.9 30.8
P/E Ratio 47.80 -740.95 78.41 48.11
Revenue 36.15 29.54 27.16 1164
EBITDA 1319.78 1567.22 1729.48 418.03
Net Income 488.8 604.52 673.87 298.25
ROA 352.62 441.9 495.25 13.84
P/B Ratio -2.93 -2.24 - 7.80
ROE 5.97 5.24 4.66 15.54
FCFF 16.38 18.22 17.85 304.44
FCFF Yield 246.63 326.52 377.13 2.33
Net Debt 1.89 2.5 2.89 -429
BVPS -506.5 -660.2 - 190.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 260.52 203.99 27.71% 325.89 429.88 -24.19% 278.13 244.22 13.89% 247.06 310.18 -20.35%
Expenses 173.34 142.59 21.57% 203.51 239.46 -15.01% 175.91 146.27 20.26% 156.52 173.50 -9.79%
EBITDA 87.17 61.40 41.97% 122.38 190.42 -35.73% 102.22 97.95 4.36% 90.54 136.68 -33.76%
EBIDTM 33.46% 30.10% 37.55% 44.30% 36.75% 40.11% 36.65% 44.06%
Other Income 13.10 13.68 -4.24% 15.54 9.38 65.67% 10.08 14.73 -31.57% 13.43 10.03 33.90%
Interest 0.02 0.06 -66.67% 0.06 0.10 -40.00% 0.06 0.10 -40.00% 0.06 0.10 -40.00%
Depreciation 18.05 17.78 1.52% 19.49 14.62 33.31% 18.67 13.26 40.80% 18.39 13.31 38.17%
PBT 82.21 57.24 43.62% 118.38 185.09 -36.04% 90.30 99.32 -9.08% 85.52 133.29 -35.84%
Tax 21.02 14.67 43.29% 28.36 43.16 -34.29% 22.51 25.23 -10.78% 22.62 34.59 -34.61%
PAT 61.19 42.57 43.74% 90.02 141.94 -36.58% 67.78 74.09 -8.52% 62.90 98.70 -36.27%
PATM 23.49% 20.87% 27.62% 33.02% 24.37% 30.34% 25.46% 31.82%
EPS 5.85 4.07 43.73% 8.61 13.57 -36.55% 6.48 7.08 -8.47% 6.01 9.44 -36.33%

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 257.49 203.99 26.23% 326.08 429.88 -24.15% 277.77 244.22 13.74% 247.06 310.18 -20.35%
Expenses 175.11 142.59 22.81% 207.55 239.46 -13.33% 178.79 146.27 22.23% 158.57 173.50 -8.61%
EBITDA 82.38 61.40 34.17% 118.53 190.42 -37.75% 98.98 97.95 1.05% 88.49 136.68 -35.26%
EBIDTM 31.99% 30.10% 36.35% 44.30% 35.63% 40.11% 35.82% 44.06%
Other Income 12.83 13.68 -6.21% 15.35 9.38 63.65% 9.98 14.73 -32.25% 13.35 10.03 33.10%
Interest 0.04 0.06 -33.33% 0.08 0.10 -20.00% 0.08 0.10 -20.00% 0.06 0.10 -40.00%
Depreciation 18.10 17.78 1.80% 19.54 14.62 33.65% 18.75 13.26 41.40% 18.39 13.31 38.17%
PBT 77.07 57.24 34.64% 114.25 185.09 -38.27% 86.85 99.32 -12.56% 83.39 133.29 -37.44%
Tax 20.65 14.67 40.76% 25.61 43.16 -40.66% 22.51 25.23 -10.78% 22.62 34.59 -34.61%
PAT 56.42 42.57 32.53% 88.65 141.94 -37.54% 64.34 74.09 -13.16% 60.77 98.70 -38.43%
PATM 21.91% 20.87% 27.18% 33.02% 23.16% 30.34% 24.60% 31.82%
EPS 5.59 4.21 32.78% 8.49 13.42 -36.74% 6.16 7.26 -15.15% 6.08 9.15 -33.55%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Net Sales 1,111.60 1,055.07 1,200.09 1,016.94 853.17 712.93 616.94 512.33 436.01 339.53 321.71 Net Sales Growth -6.45% -12.08% 18.01% 19.20% 19.67% 15.56% 20.42% 17.50% 28.42% 5.54% Cost Of Goods Sold 256.50 245.97 305.51 229.20 180.21 164.01 111.56 129.94 108.01 65.26 54.31 Gross Profit 855.10 809.11 894.57 787.74 672.96 548.92 505.37 382.39 328.00 274.27 267.40 GP Margin 76.93% 76.69% 74.54% 77.46% 78.88% 76.99% 81.92% 74.64% 75.23% 80.78% 83.12% Total Expenditure 709.28 678.00 693.24 584.75 504.59 439.01 289.01 307.79 255.29 194.31 156.16 Power & Fuel Cost - 116.20 112.23 104.97 97.65 71.64 39.86 37.30 36.29 32.90 28.86 % Of Sales - 11.01% 9.35% 10.32% 11.45% 10.05% 6.46% 7.28% 8.32% 9.69% 8.97% Employee Cost - 170.19 138.93 123.05 110.28 95.69 69.47 62.24 48.08 45.80 32.75 % Of Sales - 16.13% 11.58% 12.10% 12.93% 13.42% 11.26% 12.15% 11.03% 13.49% 10.18% Manufacturing Exp. - 43.94 38.74 37.39 38.44 32.45 21.97 24.21 21.11 17.90 18.84 % Of Sales - 4.16% 3.23% 3.68% 4.51% 4.55% 3.56% 4.73% 4.84% 5.27% 5.86% General & Admin Exp. - 54.57 52.19 48.57 45.72 31.09 22.52 22.83 23.34 17.10 10.64 % Of Sales - 5.17% 4.35% 4.78% 5.36% 4.36% 3.65% 4.46% 5.35% 5.04% 3.31% Selling & Distn. Exp. - 33.13 34.55 33.11 23.70 21.44 13.36 15.60 15.77 6.84 8.66 % Of Sales - 3.14% 2.88% 3.26% 2.78% 3.01% 2.17% 3.04% 3.62% 2.01% 2.69% Miscellaneous Exp. - 14.00 11.09 8.46 8.59 22.69 10.26 15.67 2.69 8.52 8.66 % Of Sales - 1.33% 0.92% 0.83% 1.01% 3.18% 1.66% 3.06% 0.62% 2.51% 0.65% EBITDA 402.31 377.07 506.85 432.19 348.58 273.92 327.93 204.54 180.72 145.22 165.55 EBITDA Margin 36.19% 35.74% 42.23% 42.50% 40.86% 38.42% 53.15% 39.92% 41.45% 42.77% 51.46% Other Income 52.15 52.73 44.45 33.78 35.31 23.42 13.81 31.37 17.44 17.92 9.72 Interest 0.20 0.77 1.04 3.18 9.80 6.13 1.05 1.17 0.93 1.13 1.06 Depreciation 74.60 74.33 54.37 53.59 54.03 50.05 27.52 21.25 19.31 17.62 15.00 PBT 376.41 354.71 495.88 409.19 320.05 241.16 313.17 213.49 177.92 144.39 159.22 Tax 94.51 88.17 122.91 104.46 81.93 62.59 77.83 44.53 59.53 43.90 50.40 Tax Rate 25.11% 25.09% 24.79% 25.53% 25.60% 25.95% 24.85% 20.86% 33.46% 30.40% 31.65% PAT 281.89 263.27 372.96 304.73 238.13 178.57 235.33 168.96 118.39 100.49 108.82 PAT before Minority Interest 281.89 263.27 372.96 304.73 238.13 178.57 235.33 168.96 118.39 100.49 108.82 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 25.36% 24.95% 31.08% 29.97% 27.91% 25.05% 38.14% 32.98% 27.15% 29.60% 33.83% PAT Growth -21.11% -29.41% 22.39% 27.97% 33.35% -24.12% 39.28% 42.71% 17.81% -7.65% EPS 26.95 25.17 35.66 29.13 22.77 17.07 22.50 16.15 11.32 9.61 10.40

Description TTM Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Net Sales 1,108.40 1,054.89 1,200.09 1,016.94 853.17 712.93 616.94 512.33 Net Sales Growth -6.72% -12.10% 18.01% 19.20% 19.67% 15.56% 20.42% Cost Of Goods Sold 254.86 245.67 305.51 229.20 180.21 164.01 111.56 129.94 Gross Profit 853.54 809.22 894.57 787.74 672.96 548.92 505.38 382.39 GP Margin 77.01% 76.71% 74.54% 77.46% 78.88% 76.99% 81.92% 74.64% Total Expenditure 720.02 686.95 693.24 584.75 504.59 439.01 289.01 307.79 Power & Fuel Cost - 116.20 112.23 104.97 97.65 71.64 39.86 37.30 % Of Sales - 11.02% 9.35% 10.32% 11.45% 10.05% 6.46% 7.28% Employee Cost - 176.90 138.93 123.05 110.28 95.69 69.47 57.39 % Of Sales - 16.77% 11.58% 12.10% 12.93% 13.42% 11.26% 11.20% Manufacturing Exp. - 43.94 38.74 37.39 38.44 32.48 21.97 24.21 % Of Sales - 4.17% 3.23% 3.68% 4.51% 4.56% 3.56% 4.73% General & Admin Exp. - 56.34 52.19 48.57 45.72 31.09 22.52 26.19 % Of Sales - 5.34% 4.35% 4.78% 5.36% 4.36% 3.65% 5.11% Selling & Distn. Exp. - 33.48 34.55 33.11 23.70 21.44 13.36 15.60 % Of Sales - 3.17% 2.88% 3.26% 2.78% 3.01% 2.17% 3.04% Miscellaneous Exp. - 14.42 11.09 8.46 8.59 22.66 10.26 17.15 % Of Sales - 1.37% 0.92% 0.83% 1.01% 3.18% 1.66% 3.35% EBITDA 388.38 367.94 506.85 432.19 348.58 273.92 327.93 204.54 EBITDA Margin 35.04% 34.88% 42.23% 42.50% 40.86% 38.42% 53.15% 39.92% Other Income 51.51 52.36 44.45 33.78 35.31 23.42 13.81 31.37 Interest 0.26 0.82 1.04 3.18 9.80 6.13 1.05 1.17 Depreciation 74.78 74.46 54.37 53.59 54.03 50.05 27.52 21.25 PBT 361.56 345.01 495.88 409.19 320.05 241.16 313.17 213.49 Tax 91.39 85.42 122.91 104.46 81.93 62.59 77.83 44.53 Tax Rate 25.28% 25.00% 24.79% 25.53% 25.60% 25.95% 24.85% 20.86% PAT 270.18 260.91 371.64 308.10 240.09 174.93 234.89 168.96 PAT before Minority Interest 272.69 259.23 371.64 308.10 240.09 174.93 234.89 168.96 Minority Interest 2.51 1.68 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 24.38% 24.73% 30.97% 30.30% 28.14% 24.54% 38.07% 32.98% PAT Growth -24.38% -29.79% 20.62% 28.33% 37.25% -25.53% 39.02% EPS 25.83 24.94 35.53 29.46 22.95 16.72 22.46 16.15

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17
Shareholder's Funds 2,019.75 1,812.65 1,525.25 1,291.98 1,107.16 999.67 770.08 682.50 594.36 524.68 Share Capital 10.46 10.46 10.46 10.46 9.51 9.51 9.51 9.51 9.51 9.51 Total Reserves 2,009.29 1,802.18 1,514.79 1,281.52 1,097.65 990.16 760.57 672.99 584.85 515.17 Non-Current Liabilities 49.54 37.47 31.91 32.13 243.48 207.62 55.19 22.97 27.72 39.38 Secured Loans 0.00 0.00 0.00 6.24 31.25 56.25 35.53 0.00 8.81 17.53 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 3.72 2.82 1.96 2.30 190.95 132.29 1.59 1.19 1.01 0.80 Current Liabilities 167.24 184.06 142.16 190.53 151.89 105.74 223.27 54.20 63.45 49.31 Trade Payables 101.18 113.04 94.44 93.80 83.11 46.40 71.23 33.15 39.48 29.18 Other Current Liabilities 54.82 54.97 38.32 60.26 62.70 53.58 41.79 20.93 19.26 16.58 Short Term Borrowings 0.00 0.38 0.00 0.00 4.34 5.10 0.00 0.00 4.59 1.05 Short Term Provisions 11.24 15.67 9.40 36.47 1.75 0.66 110.25 0.12 0.11 2.49 Total Liabilities 2,236.53 2,034.18 1,699.32 1,514.64 1,502.53 1,313.03 1,048.54 759.67 685.53 613.37 Net Block 786.41 794.69 575.32 592.98 572.98 546.22 239.60 229.70 188.69 181.66 Gross Block 1,160.66 1,097.16 828.31 792.80 718.85 644.29 311.19 280.91 220.92 278.60 Accumulated Depreciation 374.25 302.48 253.00 199.81 145.87 98.08 71.59 51.21 32.24 96.94 Non Current Assets 991.32 898.94 803.08 786.95 869.87 705.89 401.78 259.70 226.64 192.65 Capital Work in Progress 79.32 50.66 211.48 172.70 74.16 17.95 141.40 18.99 2.70 9.43 Non Current Investment 85.63 18.65 0.67 0.79 0.92 0.67 0.67 0.00 0.03 0.03 Long Term Loans & Adv. 32.68 12.01 12.81 11.61 220.99 140.61 19.44 10.69 35.15 1.19 Other Non Current Assets 7.28 22.93 2.81 8.87 0.82 0.45 0.67 0.31 0.07 0.33 Current Assets 1,245.22 1,135.24 896.23 727.70 632.67 607.15 646.76 499.97 458.88 420.71 Current Investments 402.06 316.54 243.70 136.93 73.47 140.99 198.11 229.33 151.03 153.90 Inventories 325.69 239.67 207.95 212.31 195.12 153.61 111.23 91.72 71.45 61.35 Sundry Debtors 460.60 521.65 349.61 273.76 232.17 177.52 183.50 158.61 219.69 179.02 Cash & Bank 9.28 1.18 47.02 43.45 88.93 60.82 2.59 3.82 2.32 1.44 Other Current Assets 47.58 28.79 26.82 45.57 42.97 74.22 151.34 16.49 14.39 25.01 Short Term Loans & Adv. 30.13 27.40 21.12 15.68 10.44 33.85 136.84 6.75 2.48 14.37 Net Current Assets 1,077.97 951.18 754.08 537.17 480.77 501.41 423.49 445.77 395.43 371.40 Total Assets 2,236.54 2,034.18 1,699.31 1,514.65 1,502.54 1,313.04 1,048.54 759.67 685.52 613.36

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Shareholder's Funds 2,017.06 1,812.72 1,526.65 1,290.00 1,103.22 999.37 770.23 Share Capital 10.46 10.46 10.46 10.46 9.51 9.51 9.51 Total Reserves 2,006.60 1,802.26 1,516.18 1,279.54 1,093.71 989.86 760.72 Non-Current Liabilities 47.58 37.47 31.91 32.13 54.40 77.43 55.19 Secured Loans 0.00 0.00 0.00 6.24 31.25 56.25 35.53 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 3.72 2.82 1.96 2.30 1.87 2.10 1.59 Current Liabilities 169.08 184.06 142.16 191.84 344.24 235.93 223.27 Trade Payables 101.91 113.04 94.44 93.80 83.11 46.40 71.23 Other Current Liabilities 55.92 54.97 38.32 61.57 65.98 53.58 41.79 Short Term Borrowings 0.00 0.38 0.00 0.00 4.34 5.10 0.00 Short Term Provisions 11.24 15.67 9.40 36.47 190.82 130.85 110.25 Total Liabilities 2,231.80 2,034.25 1,700.72 1,513.97 1,501.86 1,312.73 1,048.69 Net Block 788.55 794.69 575.32 592.98 572.98 546.22 239.60 Gross Block 1,162.94 1,097.16 828.31 792.80 719.95 645.33 311.19 Accumulated Depreciation 374.38 302.48 253.00 199.81 146.97 99.11 71.59 Non Current Assets 981.68 899.01 804.48 786.28 869.20 705.59 510.12 Capital Work in Progress 79.32 50.66 211.48 172.70 74.16 17.95 141.40 Non Current Investment 88.58 18.73 2.06 0.12 0.26 0.37 0.81 Long Term Loans & Adv. 17.94 12.01 12.81 11.61 220.99 140.61 127.63 Other Non Current Assets 7.28 22.93 2.81 8.87 0.82 0.45 0.67 Current Assets 1,250.11 1,135.24 896.23 727.70 632.67 607.15 538.58 Current Investments 402.06 316.54 243.70 136.93 73.47 140.99 198.11 Inventories 326.36 239.67 207.95 212.31 195.12 153.61 111.23 Sundry Debtors 460.20 521.65 349.61 273.76 232.17 177.52 183.50 Cash & Bank 13.58 1.18 47.02 43.45 88.93 60.82 2.59 Other Current Assets 47.92 28.79 26.82 45.57 42.97 74.22 43.15 Short Term Loans & Adv. 30.21 27.40 21.12 15.68 10.44 33.85 28.65 Net Current Assets 1,081.03 951.18 754.08 535.86 288.42 371.22 315.30 Total Assets 2,231.79 2,034.25 1,700.71 1,513.98 1,501.87 1,312.74 1,048.70

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 16 Mar 15
Cash From Operating Activity 263.78 244.52 265.47 246.00 207.47 166.81 51.98 72.79 PBT 351.43 495.88 409.19 320.05 241.16 313.17 129.34 105.88 Adjustment 38.93 28.82 40.80 48.51 49.16 17.59 5.94 8.14 Changes in Working Capital -29.12 -170.76 -81.18 -52.29 -22.06 -88.77 -38.77 -11.56 Cash after chg. in Working capital 361.25 353.94 368.82 316.28 268.26 241.99 96.50 102.46 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -97.47 -109.42 -103.35 -70.28 -60.78 -75.18 -44.52 -29.67 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -142.28 -159.99 -154.61 -157.95 -111.79 -195.20 -61.36 -61.85 Net Fixed Assets -92.16 -108.03 -74.29 -172.49 -130.77 -400.03 -67.83 Net Investments -152.50 -90.82 -106.65 -63.33 67.27 -98.61 -0.73 Others 102.38 38.86 26.33 77.87 -48.29 303.44 7.20 Cash from Financing Activity -114.51 -98.77 -99.21 -85.22 -100.16 31.12 -18.23 15.02 Net Cash Inflow / Outflow 6.98 -14.24 11.64 2.83 -4.48 2.74 -27.60 25.96 Opening Cash & Equivalents 0.90 15.14 3.50 0.67 5.14 2.41 28.56 2.60 Closing Cash & Equivalent 7.89 0.90 15.14 3.50 0.67 5.14 0.96 28.56

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 266.88 244.52 265.47 246.00 207.47 166.82 PBT 344.65 494.55 412.56 322.01 237.52 312.72 Adjustment 36.56 30.14 37.43 46.55 52.80 18.04 Changes in Working Capital -13.92 -170.76 -81.18 -52.29 -22.05 -88.76 Cash after chg. in Working capital 367.29 353.94 368.82 316.28 268.26 241.99 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -100.41 -109.42 -103.35 -70.28 -60.78 -75.18 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -142.72 -159.99 -154.61 -157.95 -111.79 -195.21 Net Fixed Assets -92.16 -108.03 -74.29 -172.49 -130.77 Net Investments -152.50 -90.82 -106.65 -63.33 67.27 Others 101.94 38.86 26.33 77.87 -48.29 Cash from Financing Activity -112.88 -98.77 -99.21 -85.22 -100.16 31.12 Net Cash Inflow / Outflow 11.28 -14.24 11.64 2.83 -4.48 2.74 Opening Cash & Equivalents 0.90 15.14 3.50 0.67 5.14 2.41 Closing Cash & Equivalent 12.19 0.90 15.14 3.50 0.67 5.14

Financial Ratios

Standalone /

Consolidated

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11
Book Value (Rs.) 193.06 173.27 145.80 123.50 105.83 95.56 246.02 403.07 317.85 241.60 ROA 12.33% 19.98% 18.96% 15.78% 12.68% 20.89% 21.89% 24.66% 26.22% 32.78% ROE 13.74% 22.35% 21.63% 19.85% 16.95% 26.60% 26.42% 29.77% 32.45% 41.68% ROCE 18.38% 29.72% 28.89% 26.48% 21.94% 33.00% 36.59% 41.71% 44.18% 56.95% Fixed Asset Turnover 0.93 1.25 1.25 1.13 1.05 1.29 1.44 1.42 1.35 1.39 Receivable days 169.90 132.49 111.87 108.22 104.87 106.80 160.03 148.42 111.49 87.54 Inventory Days 97.79 68.07 75.42 87.15 89.27 78.34 63.55 61.40 55.63 53.17 Payable days 158.95 123.94 149.88 179.16 144.10 192.42 36.90 30.92 29.60 45.56 Cash Conversion Cycle 108.75 76.63 37.41 16.22 50.04 -7.28 186.68 178.90 137.51 95.15 Total Debt/Equity 0.00 0.00 0.00 0.02 0.05 0.09 0.02 0.02 0.05 0.04 Interest Cover 454.93 477.03 129.52 33.65 40.31 300.20 109.58 238.74 144.64 156.79

Description Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 192.81 173.27 145.93 123.31 105.45 95.52 ROA 12.15% 19.90% 19.17% 15.92% 12.43% 20.89% ROE 13.54% 22.26% 21.88% 20.06% 16.64% 26.60% ROCE 18.04% 29.62% 29.13% 26.70% 21.66% 33.01% Fixed Asset Turnover 0.93 1.25 1.25 1.13 1.05 1.29 Receivable days 169.86 132.49 111.87 108.22 104.87 106.80 Inventory Days 97.92 68.07 75.42 87.15 89.27 78.34 Payable days 159.68 123.94 149.88 179.16 144.10 192.42 Cash Conversion Cycle 108.11 76.63 37.41 16.22 50.04 -7.28 Total Debt/Equity 0.00 0.00 0.00 0.02 0.05 0.09 Interest Cover 419.57 475.76 130.57 33.85 39.72 300.11

Top Investors:

nishtha jhunjhunwaladiscretionary trust

aryaman jhunjhunwala discretionary trust

aryavir jhunjhunwala discretionary trust

government pension fund global

tata aia life insurance co ltd unit linked multi cap fund

1575773 ontario inc

dsp small cap fund

axis max life insurance limited a/c reversionary bonus participating - equity

ravindra raichand dharamshi

chanakya corporate services pvt ltd

Annual Reports:

News Update:

Concord Biotech - Quarterly Results
1st Aug 2026, 00:00 AM

Read More
Concord Biotech clears PPB Kenya, NDA Uganda inspection at Unit-II formulation facility
25th Jun 2026, 12:44 PM

The inspection took place from June 18, 2026 to June 24, 2026, and was concluded successfully
Read More
Concord Biotech to acquire 27.38% stake in M/s FSGE Renewable Power
22nd Jun 2026, 14:12 PM

The investment is for installation of Wind Solar Hybrid Power Project in Gujarat
Read More
Brazilian Health Regulatory Agency completes inspection at Concord Biotech’s API manufacturing facility in Limbasi
12th Jun 2026, 15:30 PM

The inspection took place from June 8, 2026 to June 12, 2026
Read More
Concord Biotech gets USFDA’s nod for Tofacitinib Tablets
10th Jun 2026, 10:40 AM

Tofacitinib tablets are indicated for the treatment of adult patients with Moderately
Read More
Concord Biotech gets USFDA nod for Mycophenolate Mofetil for Oral Suspension
3rd Jun 2026, 10:00 AM

The U.S. market for Mycophenolate Mofetil is around $30 million
Read More

Concord Biotech Ltd.

Pharmaceuticals & Drugs

BSE: 543960 | NSE: CONCORDBIO

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Concord Biotech Ltd.

Pharmaceuticals & Drugs

BSE: 543960 | NSE: CONCORDBIO

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: